재발성/불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유건희 | - |
dc.contributor.author | 정낙균 | - |
dc.contributor.author | 조빈 | - |
dc.contributor.author | 강형진 | - |
dc.contributor.author | 신희영 | - |
dc.contributor.author | 임호준 | - |
dc.contributor.author | 서종진 | - |
dc.contributor.author | 임영탁 | - |
dc.contributor.author | 유철주 | - |
dc.contributor.author | 김순기 | - |
dc.contributor.author | 전인상 | - |
dc.contributor.author | 국훈 | - |
dc.contributor.author | 구홍회 | - |
dc.date.available | 2020-02-27T20:43:59Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2233-5250 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6776 | - |
dc.description.abstract | Background: Although the overall survival of childhood acute lymphoblastic leukemia (ALL) approaches 85-90%, the prognosis of relapsed or refractory (R/R) ALL is grave. This study aimed to identify the treatment pattern, treatment response, and overall survival of these patients. Methods: We reviewed data of 64 patients with R/R ALL whose initial diagnosis of ALL had been made between 1 and 21 years of age. Patients who received clofarabine as part of an induction regimen were excluded. Relapsed patients were limited to those who relapsed after ≥2 prior induction regimens. Treatment patterns, response rates, and overall survival were analyzed. Results: Patients’ median age was 15.0 years (range, 6.0-25.0) at the diagnosis of R/R ALL. The most frequently used agents other than steroid were vincristine (54.0%), cytarabine (44.6%), and idarubicin (36.5%), while L-asparaginase was used in only one patient. The complete remission (CR) and overall response (OR) rates were 38.1 and 42.9%, respectively. Sixteen patients (25.4%) underwent allogeneic hematopoietic stem cell transplantation (HSCT). The 5-year overall survival was 6.7%. The survival of patients with HSCT was significantly higher compared with those without HSCT (35.2% vs 0%, P=0.0097). Among 14 patients who achieved CR or CR without platelet recovery (CRp) before HSCT, the 3-year survival was 46.9%. Conclusion: The survival of Korean patients with R/R childhood ALL was dismal despite a reasonable CR rate, whereas that of those who received HSCT after CR or CRp was excellent. More treatment options are needed to improve the overall outcome of R/R childhood ALL. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한소아혈액종양학회 | - |
dc.relation.isPartOf | Clinical Pediatric Hematology-Oncology | - |
dc.title | 재발성/불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구 | - |
dc.title.alternative | A Multicenter Retrospective Analysis on the Treatment Pattern and Outcome in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.15264/cpho.2017.24.2.101 | - |
dc.identifier.bibliographicCitation | Clinical Pediatric Hematology-Oncology, v.24, no.2, pp.101 - 106 | - |
dc.identifier.kciid | ART002276355 | - |
dc.citation.endPage | 106 | - |
dc.citation.startPage | 101 | - |
dc.citation.title | Clinical Pediatric Hematology-Oncology | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | 전인상 | - |
dc.subject.keywordAuthor | Childhood | - |
dc.subject.keywordAuthor | Acute lymphoblastic leukemia | - |
dc.subject.keywordAuthor | Relapsed | - |
dc.subject.keywordAuthor | Refractory | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.